LENZ Therapeutics (LENZ) News Today $32.63 +2.35 (+7.76%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wellington Management Group LLP Takes $585,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Wellington Management Group LLP purchased a new position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 24,621 shares of the company's stock, valued at approximately $585,December 21 at 3:40 AM | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 4.1% - Time to Sell?LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1% - Should You Sell?December 20 at 12:37 PM | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Trading 5.8% Higher - Time to Buy?LENZ Therapeutics (NASDAQ:LENZ) Shares Up 5.8% - Here's WhyDecember 19 at 3:15 PM | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average PT from BrokeragesDecember 18 at 1:15 AM | americanbankingnews.comCharles Schwab Investment Management Inc. Has $2.93 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Charles Schwab Investment Management Inc. increased its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 197.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,371 shares ofDecember 16, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from AnalystsShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus rating of "Buy" from the seven analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating onDecember 15, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Invests $743,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ)The Manufacturers Life Insurance Company bought a new position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 31,309 shares of the compaDecember 14, 2024 | marketbeat.com139,357 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Bought by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC purchased a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 139,357 shares of the company's stock, valued at apDecember 4, 2024 | marketbeat.comWe're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash WiselyDecember 1, 2024 | finance.yahoo.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.7% - Here's WhyLENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 4.7% - Here's What HappenedNovember 29, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by BBR Partners LLCBBR Partners LLC increased its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 100.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,000 shares of the coNovember 28, 2024 | marketbeat.comLENZ Therapeutics: Time For A PauseNovember 27, 2024 | seekingalpha.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Buy" by AnalystsShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating tNovember 20, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 6.3% - Here's WhyLENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3% - What's Next?November 15, 2024 | marketbeat.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 15, 2024 | investorplace.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 12, 2024 | investorplace.comLENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year High - What's Next?LENZ Therapeutics (NASDAQ:LENZ) Reaches New 1-Year High - Here's What HappenedNovember 12, 2024 | marketbeat.comLENZ Therapeutics to Participate in Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024November 11, 2024 | investorplace.comLeerink Partnrs Brokers Boost Earnings Estimates for LENZLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at Leerink Partnrs raised their Q4 2024 earnings per share estimates for LENZ Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earninNovember 11, 2024 | marketbeat.comHC Wainwright Has Positive Forecast for LENZ FY2024 EarningsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for LENZ Therapeutics in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst M. Caufield now anticipates that the company wNovember 11, 2024 | marketbeat.comFY2024 EPS Estimate for LENZ Therapeutics Boosted by AnalystLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at William Blair boosted their FY2024 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a report issued on Wednesday, November 6th. William Blair analyst L. Hanbury-Brown now expects that the company wiNovember 11, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comPatent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial StabilityNovember 8, 2024 | markets.businessinsider.comLENZ Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comLenz Therapeutics price target raised to $36 from $32 at LeerinkNovember 7, 2024 | markets.businessinsider.comLENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comLENZ Therapeutics (LENZ) Set to Announce Earnings on WednesdayLENZ Therapeutics (NASDAQ:LENZ) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comLeerink Partners Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)October 30, 2024 | markets.businessinsider.comLENZ reports positive Chinese study data for far-sightedness drugOctober 29, 2024 | msn.comLENZ Therapeutics Reports Positive Phase 3 Results For LNZ100 In Presbyopia Trial In ChinaOctober 28, 2024 | markets.businessinsider.comWhy LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketOctober 28, 2024 | benzinga.comLENZ Therapeutics Shares Climb After Presbyopia Trial Hits EndpointsOctober 28, 2024 | marketwatch.comCORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100October 27, 2024 | globenewswire.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Recommendation of "Buy" by AnalystsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) has earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned aOctober 26, 2024 | marketbeat.comLenz Therapeutics announces FDA acceptance of NDA for LNZ100October 22, 2024 | markets.businessinsider.comLENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition TreatmentOctober 21, 2024 | marketwatch.comWhy LENZ Therapeutics Stock Hit A New 52-Week High TodayOctober 21, 2024 | benzinga.comFDA Accepts LENZ Therapeutics' NDA For LNZ100 To Treat PresbyopiaOctober 21, 2024 | markets.businessinsider.comLENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of PresbyopiaOctober 21, 2024 | globenewswire.comFY2028 Earnings Forecast for LENZ Issued By Leerink PartnrsLENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at Leerink Partnrs upped their FY2028 earnings per share estimates for shares of LENZ Therapeutics in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the coOctober 18, 2024 | marketbeat.comMarshall Wace LLP Makes New $390,000 Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ)Marshall Wace LLP purchased a new stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,554 shares of the company's stock, valued at aOctober 11, 2024 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Buy" by BrokeragesShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned a consensus recommendation of "Buy" from the seven analysts that are presently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy ratingOctober 1, 2024 | marketbeat.comLENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical ConferencesSeptember 30, 2024 | finance.yahoo.comRaymond James Initiates Coverage of LENZ Therapeutics (LENZ) with Outperform RecommendationSeptember 29, 2024 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Raymond JamesRaymond James initiated coverage on LENZ Therapeutics in a research report on Friday. They set an "outperform" rating and a $37.00 price target for the company.September 27, 2024 | marketbeat.comBank of New York Mellon Corp Buys 28,556 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)Bank of New York Mellon Corp raised its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 255.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,737 shares of the compSeptember 23, 2024 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 7.8%LENZ Therapeutics (NASDAQ:LENZ) Shares Up 7.8%September 13, 2024 | marketbeat.comLENZ Therapeutics Insiders Up US$178k On US$551.1k InvestmentSeptember 12, 2024 | finance.yahoo.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Recommendation of "Buy" from AnalystsShares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have received a consensus rating of "Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price amSeptember 6, 2024 | marketbeat.com Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. LENZ Media Mentions By Week LENZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼1.080.60▲Average Medical News Sentiment LENZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼62▲LENZ Articles Average Week Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DNLI News Today TWST News Today VCEL News Today SWTX News Today KYMR News Today IOVA News Today BEAM News Today RXRX News Today APGE News Today IBRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LENZ Stock Alerts